Choroidal involvement, cystoid macular edema, inflammation of the optic nerve, and retinal vasculitis were reported in 25.0% (n = 60), 58.5% (n = 141), 18.8% (n = 45), and 30.4% (n = 73) of these patients, respectively.Table 1Baseline demographics and characteristicsVariablesTreated with DEX on day 0 (N = 97)Not treated with DEX on day 0 (N = 144)Total population (N = 241)Mean (SD) age, years60.6 (14.3)52.7 (17.2)55.9 (16.5) 95% CI57.7–63.449.9–55.653.8–58.0 N94140234Sex, n (%) Female59 (60.8)89 (62.2)148 (61.7) Male38 (39.2)54 (37.8)92 (38.3) N97143240Bilateral uveitis, n (%)63 (66.3)105 (73.9)168 (70.9) N95142237Mean (SD) duration of uveitis, years5.0 (5.6)6.8 (9.0)6.1 (7.9) 95% CI3.8–6.15.3–8.35.0–7.1 N94140234Etiology, n (%) Idiopathic39 (40.2)49 (34.3)88 (36.7) Sarcoidosis11 (11.3)20 (14.0)31 (12.9) Birdshot disease10 (10.3)21 (14.7)31 (12.9) Behcet’s disease3 (3.1)7 (4.9)10 (4.2) Multiple sclerosis2 (2.1)3 (2.1)5 (2.1) Retinal vasculitis2 (2.1)3 (2.1)5 (2.1) Pars planitis03 (2.1)3 (1.3) Vogt-Koyanagi-Harada disease1 (1.0)2 (1.4)3 (1.3) Other29 (29.9)35 (24.5)64 (26.7) N97143240Study eye, n (%) Right59 (60.8)75 (52.4)134 (55.8) Left38 (39.2)68 (47.6)106 (44.2) N97143240Treatment status of uveitis, n (%) Treatment-naïve19 (20.0)28 (19.7)47 (19.8)  95% CI14.8–24.912.0–28.013.2–26.3 DEX-naïve24 (25.3)83 (58.5)107 (45.1)  95% CI16.5–34.050.3–66.638.8–51.5 Prior DEX treatment52 (54.7)31 (21.8)83 (35.0)  95% CI44.7–64.715.0–28.628.9–41.1 N95142237Mean (SD) DEX injections, na7.5 (3.7)2.1 (1.0)5.6 (4.0) 95% CI5.4–9.51.3–3.03.9–7.3 N15823Mean (SD) BCVA, letters60.9 (18.3)66.3 (21.5)64.1 (20.4) 95% CI57.2–64.662.7–69.961.4–66.7 N97138235Mean (SD) CRT, µm424.8 (132.8)333.6 (118.0)370.4 (131.7) 95% CI397.2–452.3313.6–353.6353.2–387.6 N92136228Mean (SD) IOP, mmHg13.9 (3.6)14.2 (4.8)14.1 (4.4) 95% CI13.2–14.713.4–15.013.5–14.7 N92137229Vitreous haze score0.6 (0.8)0.5 (0.7)0.5 (0.7) 95% CI0.4–0.80.4–0.60.4–0.6 N82135217Presence of macular edema, n (%)66 (70.2)62 (44.0)128 (54.5) 95% CI61.0–79.535.8–52.248.1–60.8 N94141235Presence of inflammation-associated pathology, n (%)b82 (84.5)109 (75.7)191 (79.3) 95% CI77.3–91.768.7–82.774.1–84.4 N97144241Presence of comorbidities, n (%) Generalc38 (39.2)55 (38.2)93 (38.6)  95% CI29.5–48.930.3–46.132.4–44.7 Ophthalmicd86 (88.7)102 (70.8)188 (78.0)  95% CI82.3–95.063.4–78.372.8–83.2  Cataract (surgically operated or not)74 (76.3)81 (56.3)155 (64.3)  95% CI67.8–84.848.1–64.458.3–70.4 N97144241BCVA best corrected visual acuity, CI confidence interval, CRT central retinal thickness, DEX dexamethasone intravitreal implant, IOP intraocular pressure, SD standard deviationaAnalysis excluded treatment-naïve patientsbIncluded at least one of the following: choroidal involvement, retinal vascularity, inflammation of the optic nerve, and cystoid macular edemacIncluded at least one of the following: diabetes (type 1 or 2), hypercholesterolemia, hypertension, and cardiovascular diseasesdIncluded at least one of the following: epiretinal membrane, cataract, glaucoma, ocular hypertension, age-related macular degeneration, and vitreous hemorrhage